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Trust But Verify*William A. Zoghbi, MDV alvular aortic stenosis (AS) has been recog-nized for decades as a progressive valvulardisease that carries signiﬁcant morbidity
and mortality. In normal ﬂow conditions, AS is de-
ﬁned as severe when the mean transvalvular pressure
gradient is $40 mm Hg and the valve area is reduced
below 1 cm2 (<0.8 cm2 for more speciﬁcity) (1).
Because of the dependency of gradients on ﬂow,
lower gradients may be seen with severe aortic steno-
sis (SAS) in reduced ﬂow conditions, be it in the pres-
ence of depressed or normal left ventricular (LV)
function. Low-gradient severe aortic stenosis (LGSAS)
with preserved LV ejection fraction (EF) has been
highlighted since 2007 (2) as an entity that portends
a poor prognosis, with few inconsistencies. In this
issue of the Journal, Dayan et al. (3) report a meta-
analysis of studies on the clinical outcome and impact
of aortic valve replacement (AVR) in patients with
LGSAS and preserved EF that summarizes the current
knowledge of this entity and its implications as to the
patient substrate, prognosis, and management.SEE PAGE 2594THE STUDY
The meta-analysis comprises 18 studies within the
past 10 years, in which either overall mortality of
patients with LGSAS was compared with those with
high-gradient or moderate AS, or a comparison of*Editorials published in Journal of the American College of Cardiology
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contents of this paper to disclose.outcome of such patients undergoing AVR versus
conservative management was available. All groups
had preserved EF. Patients were also subdivided into
low-ﬂow (<35 ml/m2) and normal-ﬂow AS when
possible. Symptoms were present in 56% of patients
with LGSAS, and 58% underwent AVR. Overall, pa-
tients with low-ﬂow LGSAS had a higher risk of
mortality compared with any other cohort of SAS
(normal-ﬂow LG or high gradient) or moderate AS.
Valve replacement (most being surgical AVR) seemed
to improve survival compared with conservative
medical therapy in all cohorts of LGSAS.
The authors conducted a thorough and rigorous
meta-analysis; however, it is the robustness of the
individual studies that ultimately affects the overall
results and conclusions of such analysis. Of the 18
studies included, various comparisons of either prog-
nosis or effect of AVR could be performed in a subset of
these reports. All investigations were retrospective,
nonrandomized, and unmatched, with the exception
of the echo substudy of the PARTNER (Placement of
Aortic Transcatheter Valves) trial (4), where the pop-
ulation was deﬁned prospectively and randomized per
treatment strategy; coronary artery disease requiring
revascularization, a determinant of outcome and a
confounding variable in most reports, was excluded
from the study. No individual data were available to
adjust for confounding variables and the duration of
follow-up was variable. Despite these limitations, the
current investigation sheds light on the entity of
LGSAS with preserved EF and its outcome, an inter-
esting and challenging clinical scenario.
LGSAS WITH PRESERVED LVEF
This hemodynamic situation can arise from different
clinical conditions and causes, including a low-
normal or mildly reduced stroke volume in patients
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2605with normal LV size and borderline or mildly de-
pressed LV systolic function, a small LV related to a
small body size and/or concentric hypertrophy or
remodeling yielding a lower stroke volume, calcula-
tion errors in determining stroke volume and valve
area by Doppler echocardiography (underestimation
of LV outﬂow diameter because of its shape or calci-
ﬁcations, or malposition of the Doppler sample vol-
ume), and an internal inconsistency in the deﬁnition
of SAS by current guidelines relating to the cutoff of
valve area in relation to gradient and jet velocity
(1 cm2 cutoff is sensitive but less speciﬁc for hemo-
dynamically SAS, whereas 0.8 cm2 corresponds more
closely to the gradient/velocity cutoffs of SAS) (1,5,6).
In the meta-analysis, patients with low-ﬂow LGSAS
had overall clinical characteristics that were consis-
tent among studies: compared with high-gradient
SAS, they were older and had a higher prevalence of
coronary artery disease, diabetes mellitus, and hy-
pertension. As such, low-ﬂow LGSAS with preserved
LVEF is a clinical condition that is frequently
accompanied by comorbidities that inherently have
an impact on prognosis and may explain, at least in
part, the worse outcome observed.
In this spectrum of LGSAS, those with normal ﬂow
and preserved LVEF represent another heterogenous
group as acknowledged by the authors, because their
valve area is likely higher than those with low-ﬂow
LGSAS. Many of these patients have pseudo-SAS,
because their valve area usually is just below 1 cm2.
Of interest, in the current study, the high prevalence
of comorbidities in this population was similar to
those with low-ﬂow LGSAS and may in part account
for the comparable prognosis of these 2 patient pop-
ulations. Ascertaining severity of AS in LGSAS is
crucial for patient management; asymptomatic pa-
tients can be managed medically until symptoms
arise, because their prognosis may be similar to
moderate AS in the setting of lesser AS severity and
fewer comorbidities (7).
EFFECT OF AVR ON PROGNOSIS IN LGSAS
AVR in patients with SAS improves survival in
symptomatic patients. In the current study, AVR
improved survival compared with conservative ther-
apy in patients with LGSAS (low and normal ﬂow);
however, patients with high-gradient SAS, who also
had fewer comorbidities, had the greatest beneﬁt.
With the limitations to the studies already noted, the
question is whether the survival beneﬁt is over-
estimated because the populations were not matched
or randomized, leaving the medically treated cohorts
with more comorbidities and higher overall riskfor the same severity of AS. However, this cannot
be resolved from the current analysis. The echo sub-
study of the PARTNER trial provides at present the
best investigation to evaluate the comparative effect
of AVR versus medical therapy on outcome in symp-
tomatic patients with LGSAS who had sufﬁcient
comorbidities and risk to be deemed inoperable (4).
Valve area was severe at entry (<0.8 cm2). Outcome
with AVR was clearly superior to conservative treat-
ment; low ﬂow was the most important prognostic
imaging parameter in all patients (4). Although most
studies were not controlled, the ﬁndings from the
meta-analysis are still consistent with current guide-
lines for a IIa recommendation for AVR in symptom-
atic patients with LGSAS (1).
In the meta-analysis, studies that included patients
with moderate AS (valve area >1 cm2) raise a concern
of patient selection: 59% had symptoms similar to or
higher than those with SAS, and 35% of them under-
went AVR. This is an unusually high prevalence of
symptoms and AVR in moderate AS and should not be
extrapolated to the AS population at large, because
moderate AS has been shown to have an intermediate
prognosis. Of interest is that in the 2 studies where
AVR was compared with medical therapy in moderate
AS, there was no advantage of AVR, as would be
expected.
TRUST BUT VERIFY
Patients with LGSAS present a diagnostic and thera-
peutic challenge to the clinician. The terminology can
be complicated, because it incorporates measure-
ments of gradient, ﬂow, LVEF, and valve area.
Although cutoffs have been proposed for what con-
stitutes low-ﬂow, LG, and severe valve area, the
clinician should realize the continuum in AS disease
and the frequent straddling of these parameters in a
particular patient. It is important to recognize that
patients with LGSAS can be asymptomatic, and their
prognosis may be similar to moderate AS if their valve
area is moderately severe and they have few comor-
bidities. In the symptomatic patient, ascribing
symptoms to an underlying etiology may be chal-
lenging because symptoms may be related to the
comorbidities and/or the AS. Furthermore, not all
patients with “severe” AS are created equal. The
smaller the valve area in patients with LGSAS,
the more conﬁdent one is of the severity of the dis-
ease, its related symptoms, and the need for an
intervention.
In LGSAS with preserved LVEF, and particularly
in low-ﬂow conditions, ascertaining the severity of
AS is of paramount importance. Because Doppler
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2606echocardiography is the main ﬁrst-line diagnostic
modality, the echocardiographer needs to ensure that
the data on quantitated ﬂow and derived valve area
are internally consistent with low ﬂow through the AS
(e.g., small LV volume, concomitant mitral regurgi-
tation, and so forth). If inconsistencies occur and
cannot be resolved, they should be communicated
to the clinician and additional testing suggested for
further evaluation of AS severity, such as dobuta-
mine echocardiography, cardiac magnetic resonance,computed tomography, or invasive hemodynamics,
as deemed appropriate—another facet of the heart
team approach to cardiac care in valvular heart
disease.
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